CHAPTER 1. INTRODUCTION
1.1. Market Definition
1.2. Executive Summary
1.3. The Scope of the Study
CHAPTER 2. RESEARCH METHODOLOGY
2.1. Secondary Research
2.2. Primary Research
2.3. Analytic Tools and Model
2.4. Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5. Expert Validation
2.6. Study Timeline
CHAPTER 3. MARKET ANALYSIS
3.1. Industry Value Chain Analysis
3.2. Porter's Five Force Analysis
3.2.1. Bargaining Power of Buyers
3.2.2. Bargaining Power of Suppliers
3.2.3. Threats of Substitutes
3.2.4. Threats of New Entrants
3.2.5. Degree of Competition
3.3. PESTLE Analysis
3.3.1. Political
3.3.2. Economical
3.3.3. Social
3.3.4. Technological
3.3.5. Legal
3.3.6. Environmental
3.4. SWOT Analysis
3.4.1. Strengths
3.4.2. Weakness
3.4.3. Opportunities
3.4.4. Threats
3.5. Y-O-Y Analysis
CHAPTER 4. MARKET DYNAMICS
4.1. Market Drivers
4.1.1. Rising incidences of spine and bone disorders
4.1.2. Growing geriatric population and changing lifestyles
4.1.3. Approving healthcare reforms and regulatory scenario
4.2. Market Restraints & Challenges
4.2.1. Slow penetration of newly launched pain management drugs
4.2.2. Prescription drug exploitation
4.3. Market Opportunities
4.3.1. Advancements in treatments and largely untapped market in developing economies
CHAPTER 5. GLOBAL UPPER BACK PAIN MARKET – BY DIAGNOSTIC TESTS
5.1. Computerized Tomography (CT)
5.2. X-Ray
5.3. Discography
5.4. MRI
5.5. Electrodiagnostics
5.6. Medial Branch Nerve Block
5.7. Bone Mineral Density Exam
5.8. Others
CHAPTER 6. GLOBAL UPPER BACK PAIN MARKET – BY DRUGS & THERAPIES
6.1. By Drugs
6.1.1. Analgesic Medications
6.1.2. Anticonvulsants
6.1.3. Antidepressants
6.1.4. Counter-Irritants
6.1.5. Nonsteroidal Anti-Inflammatory Drugs
6.1.5.1. Ibuprofen
6.1.5.2. Naproxen
6.1.5.3. COX-2 Inhibitors
6.1.6. Steroid Injections
6.1.7. Others
6.2. By Therapies
6.2.1. Physical Therapy
6.2.2. Rehabilitation Exercises
6.2.3. Others
CHAPTER 7. GLOBAL UPPER BACK PAIN MARKET – BY SURGERY
7.1. Corpectomy or Vertebrectomy
7.2. Spinal Laminectomy
7.3. Foraminotomy
7.4. Intradiscal electrothermal therapy
7.5. Discectomy/Microdiscectomy
7.6. Spinal Fusion
7.7. Artificial Disc Replacement
7.8. Facetectomy
7.9. Others
CHAPTER 8. GLOBAL UPPER BACK PAIN MARKET – BY END USER
8.1. Hospitals
8.2. Clinics
8.3. Ambulatory Surgical Centers
8.4. Others
CHAPTER 9. GLOBAL UPPER BACK PAIN MARKET - BY GEOGRAPHY
9.1. Introduction
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.2.3. Mexico
9.2.4. Costa Rica
9.3. South America
9.3.1. Brazil
9.3.2. Argentina
9.3.3. Chile
9.3.4. Columbia
9.3.5. Others
9.4. Europe
9.4.1. U.K.
9.4.2. Germany
9.4.3. France
9.4.4. Italy
9.4.5. Spain
9.4.6. Russia
9.4.7. Netherlands
9.4.8. Switzerland
9.4.9. Poland
9.4.10. Others
9.5. APAC
9.5.1. China
9.5.2. Japan
9.5.3. India
9.5.4. South Korea
9.5.5. Australia & New Zealand
9.5.6. Malaysia
9.5.7. Singapore
9.5.8. Others
9.6. Middle East & Africa
9.6.1. UAE
9.6.2. Saudi Arabia
9.6.3. Iran
9.6.4. Iraq
9.6.5. Qatar
9.6.6. South Africa
9.6.7. Algeria
9.6.8. Morocco
9.6.9. Nigeria
9.6.10. Egypt
9.6.11. Others
CHAPTER 10. GLOBAL UPPER BACK PAIN MARKET - COMPANY PROFILES
10.1. Abbott Laboratories
10.2. Eli Lilly and Company
10.3. Pfizer, Inc.
10.4. Allergen, Inc.
10.5. Bayer AG
10.6. Valent Pharmaceuticals International, Inc.
10.7. Boehringer Ingelheim GmbH
10.8. Bristol-Myers Squibb
10.9. WEX Pharmaceuticals
10.10. Zynerba Pharmaceuticals
10.11. Axsome Therapeutics, Inc.
10.12. Mesoblast Inc.
10.13. Stayble Therapeutics AB
10.14. Norman Interventional Pain Management
10.15. Adynxx, Inc.
CHAPTER 11. GLOBAL UPPER BACK PAIN MARKET - COMPETITIVE
LANDSCAPE
11.1. Market Share Analysis
11.2. Strategies adopted by top companies
11.3. Mergers, Acquisitions, Collaborations & Agreements
CHAPTER 12. MARKET INSIGHTS
12.1. Industry Experts Insights
12.2. Analysts Opinions
12.3. Investment Opportunities
CHAPTER 13. APPENDIX
13.1. List of Tables
13.2. List of Figures
